Monday, November 12, 2018 12:48:57 PM
If the drugs can be combined w PD-1s effectively (easier said than done) then that could transform a drug from "incremental" to "innovative". It also has the added commercial benefit of setting the PD-1 apart from the pack so could really lead to a large premium in any BD deal.
Funny that is exactly what I was thinking. My task is to advise a company entering the oncology space on where there are gaps that need to be addressed, therapeutic areas where opportunity still exists.
Keep the insights coming
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
